Echinocystic acid prevents obesity and fatty liver via interacting withFABP1

Citations Over TimeTop 14% of 2023 papers

Abstract

Long-term high-fat diet (HFD) will lead to obesity and their complications. Echinocystic acid (EA), a triterpene, shows anti-inflammatory and antioxidant effects. We predict that EA supplementation can prevent obesity, diabetes, and nonalcoholic steatohepatitis. To test our hypothesis, we investigated the effects of EA supplementation on mice with HFD-induced obesity in vivo and in vitro by adding EA to the diet of mice and the medium of HepG2 cells, the protein target of EA was analyzed by molecular docking. The results showed that EA ameliorated obesity and inhibited blood triglyceride and liver triglyceride concentrations than those in the HFD groups. The data on molecular docking indicated that FABP1 was a potential target of EA. Further experimental results confirmed that EA affected the triglyceride level by regulating the function of FABP1. This study may provide a new potential inhibitor for FABP1 and a new strategy for the treatment of obesity.

Related Papers

• → Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?(2012)215 cited
• → Investigation of Hypertriglyceridemia in Healthy Miniature Schnauzers(2007)68 cited
• → Investigation of Hypertriglyceridemia in Healthy Miniature Schnauzers(2007)67 cited
• → Non-alcoholic steatohepatitis(2006)15 cited
• → Categorization and complication of non-alcoholic fatty liver disease(2022)1 cited